No takes yet. Share an insight, caveat, or question.
Phase I/II trial shows potential activity and safety of intrathecal PD-1 inhibitor plus pemetrexed in leptomeningeal metastases.
Pan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: